Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Wetzel, J; Pilz, S; Grübler, MR; Fahrleitner-Pammer, A; Dimai, HP; von Lewinski, D; Kolesnik, E; Perl, S; Trummer, C; Schwetz, V; Meinitzer, A; Belyavskiy, E; Völkl, J; Catena, C; Brandenburg, V; März, W; Pieske, B; Brussee, H; Tomaschitz, A; Verheyen, ND.
Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trial.
J Clin Hypertens (Greenwich). 2017; 19(11):1173-1180
Doi: 10.1111/jch.13064
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Verheyen Nicolas Dominik
- Wetzel Julia
- Co-authors Med Uni Graz
- Belyavskiy Evgeny
- Brussee Helmut
- Dimai Hans Peter
- Fahrleitner-Pammer Astrid
- Grübler Martin
- Kolesnik Ewald
- März Winfried
- Meinitzer Andreas
- Perl Sabine
- Pieske Burkert Mathias
- Pilz Stefan
- Theiler-Schwetz Verena
- Tomaschitz Andreas
- Trummer Christian
- von Lewinski Dirk
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Patients with primary hyperparathyroidism are at increased risk for high blood pressure, vascular stiffening, and left ventricular hypertrophy, but previous studies have failed to demonstrate the direct associations with circulating parathyroid hormone (PTH) levels. The authors investigated cross-sectional relationships between PTH and 24-hour pulse wave velocity, nocturnal systolic blood pressure, and left ventricular mass index in patients with primary hyperparathyroidism who were treatment-naive with cinacalcet, renin-angiotensin-aldosterone-system inhibitors, and thiazide or loop diuretics. In 76 patients, mean±SD of pulse wave velocity, nocturnal systolic blood pressure, and left ventricular mass index values were 9.3±1.8 m/s, 116.6±17.0 mm Hg, and 92.8±23.0 g/m². In multivariate linear regression analyses with adjustment for potentially confounding parameters, PTH was independently associated with nocturnal systolic blood pressure (adjusted ß coefficient=.284, P=.040), mean 24-hour pulse wave velocity (ß=.199, P=.001), and left ventricular mass index (ß=.252, P=.025). PTH may promote vascular and cardiac remodeling in primary hyperparathyroidism. Interventional trials are needed to test the antihypertensive and cardioprotective effects of PTH-inhibitory treatment strategies. ©2017 Wiley Periodicals, Inc.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Antihypertensive Agents - pharmacology
- Blood Pressure - physiology
- Blood Pressure Monitoring, Ambulatory - methods
- Cardiotonic Agents - pharmacology
- Cardiovascular Diseases - blood
- Cardiovascular Diseases - epidemiology
- Cardiovascular Diseases - etiology
- Cardiovascular Diseases - prevention & control
- Echocardiography - methods
- Female -
- Heart Ventricles - pathology
- Humans -
- Hyperparathyroidism, Primary - blood
- Hyperparathyroidism, Primary - complications
- Hyperparathyroidism, Primary - diagnosis
- Hyperparathyroidism, Primary - physiopathology
- Hypertension - blood
- Hypertension - diagnosis
- Hypertension - drug therapy
- Hypertension - physiopathology
- Male -
- Middle Aged -
- Organ Size -
- Parathyroid Hormone - blood
- Pulse Wave Analysis - methods
- Find related publications in this database (Keywords)
- ambulatory blood pressure monitoring
- blood pressure
- left ventricular mass
- parathyroid hormone
- primary hyperparathyroidism
- pulse wave velocity